Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells

Makoto Isono*, Kazuki Okubo, Takako Asano & Akinori Sato

Checkpoint kinases (CHKs) are involved in the DNA damage response in many cancer cells. CHK inhibitors have been used in clinical trials in combination with chemotherapeutics; however, their effect against bladder cancer remains unclear. Here, we investigated the efficacy of combining gemcitabine with MK-8776, a novel CHK1 inhibitor, in four bladder cancer cell lines. The effects of gemcitabine and MK-8776 on cell viability, clonogenicity, cell cycle, and apoptosis were examined alongside in vivo efficacy using murine xenograft tumor models. Combined treatment inhibited the viability and colony formation of bladder cancer cells compared to either single treatment. Although gemcitabine (10 nM) alone increased the cell number in S-phase, it increased the cell number in sub-G1 phase when combined with MK-8776 (0.5 µM). Combined treatment enhanced cleaved poly[ADP-ribose]-polymerase expression alongside the number of annexin-V-positive cells, indicating the induction of apoptosis. In vivo, administration of gemcitabine and MK-8776 was well tolerated and suppressed tumor growth. Mechanistically, the combined treatment elevated γH2A.X and suppressed Rad51 expression. Our study demonstrates that MK-8776 and gemcitabine combined induces apoptosis and suppresses proliferation in bladder cancer cells by inhibiting CHKs and DNA repair. Therefore, CHK1 inhibition combined with gemcitabine may be a potential treatment for bladder cancer.

Bladder carcinoma accounts for 7% of all cancer cases, and approximately 30% of all newly diagnosed bladder cancers invade muscle, while 50% can quickly progress and metastasize. Unfortunately, the clinical outcomes of systemic therapy in patients with locally advanced or metastatic bladder cancer are poor. Systemic cisplatin-based combination chemotherapies are the standard first-line treatments for bladder cancer; however, despite an initial response rate of around 50%, many patients suffer tumor relapse within five years. Furthermore, over half of all patients with bladder cancer display renal insufficiency, comorbidities, or frailty, and thus are ineligible for cisplatin-based chemotherapies. The treatment options available for metastatic bladder cancer have recently improved due to the clinical development of second-line immunotherapies such as atezolizumab; however, patients with metastatic bladder cancer display partial or complete response rates of just 20–30% for checkpoint immunotherapies, and the median overall survival following atezolizumab treatment is approximately 7.9 months. Therefore, further studies are required to identify a novel treatment strategy for patients with metastatic bladder cancer.

Since cells are exposed to stress by genotoxic agents, DNA repair pathways are required to preserve the genomic code. Following DNA damage, checkpoint kinases (CHKs) arrest the cell cycle, providing time for DNA repair before cells with DNA damage enter mitosis. In response, transiently-activated ataxia telangiectasia mutated (ATM) binds immediately to DNA double-strand breaks (DSBs), while the presence of single-stranded DNA at stalled replication forks activates ataxia telangiectasia and Rad3-related (ATR), followed by CHK1. Activated CHK1 phosphorylates various downstream effectors that cause the cell cycle to stall at the intra-S phase and G2/M phase until DNA damage is repaired. To survive following DNA damage, p53 mutant cells rely on S or G2 checkpoints, in which CHKs have vital functions, whereas cells with wild-type p53 can arrest the cell cycle at the G1 checkpoint for DNA repair. Notably, alterations in the p53 gene have been reported in almost all invasive bladder cancer cells, and CHK1 protein expression has been associated with clinical–pathological...
characteristics in bladder cancer. Therefore, CHK1 inhibition may abrogate cell cycle arrest and allow bladder cancer cells to enter mitosis with unrepaired DNA damage, leading to cell death.

Gemcitabine is a nucleoside analog that has been used as a chemotherapeutic agent for over 20 years. In cells, gemcitabine is phosphorylated and incorporated into replicating DNA strands, thereby terminating DNA synthesis, inducing DNA damage, and activating the DNA damage response. Experimental CHK inhibitors have undergone early-phase clinical trials both as monotherapies and in combination with drugs that directly damage DNA. Consequently, the selective CHK1 inhibitor MK-8776 has entered clinical trials for the treatment of certain solid tumors and acute leukemia; however, it remains unclear how CHK1 inhibition by MK-8776 triggers chemosensitization in bladder cancer cells. In this study, we investigated whether the co-administration of MK-8776 influences the cytotoxic effects of gemcitabine in bladder cancer cells and examined the possible underlying mechanisms.

Results

Inhibition of bladder cancer cell growth. We initially examined whether MK-8776 enhances the cytotoxic effects of gemcitabine in bladder cancer cells. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphonyl)-2H-tetrazolium (MTS) assay revealed that relative cell viability was lower in the four investigated bladder cancer cell lines treated with the combination of gemcitabine and MK-8776 than in those treated with each agent alone (Fig. 1a). In addition, the combination index (CI) value demonstrated that gemcitabine and MK-8776 exerted a synergistic effect (CI < 1) against bladder cancer cells under most treatment conditions (Table 1).

Similarly, combined treatment with gemcitabine and MK-8776 suppressed the colony formation of cancerous bladder cells (Fig. 1b, Fig. S1). Photomicrographs revealed marked morphological changes in bladder cancer cells treated with gemcitabine and MK-8776. After 24 h of treatment with gemcitabine alone or combined with MK-8776, bladder cancer cells were characterized by increased cell size and cell flattening compared to those treated with DMSO or MK-8776 alone, while the number of detached or shrunken cells increased after 48 h of treatment with gemcitabine and MK-8776, indicative of apoptosis (Fig. 1c, Fig. S2).

Next, we carried out in vivo experiments to evaluate the antitumor effects of treatment with gemcitabine and MK-8776 for 15 days. Combined treatment reduced the volume of tumor nodules relative to DMSO or MK-8776 alone; however, no significant difference in tumor size was observed between the gemcitabine and combination groups (Fig. 1d). Furthermore, mice treated with the combination did not display any remarkable weight loss (Fig. 1e). Thus, the combination of gemcitabine and MK-8776 was shown to inhibit bladder cancer cell growth both in vitro and in vivo.

Gemcitabine and MK-8776 induce cell cycle disturbances. Next, we performed flow cytometry experiments to investigate the effects of the drug combination on cell cycle distribution. Gemcitabine alone and the combination treatment for 24 h increased the number of bladder cancer cells in S-phase (Fig. 2a, Fig. S3); however, this effect appeared to subside after 48 h of gemcitabine treatment alone. Conversely, the combination led to an increase in the sub-G1 fraction of all investigated cell lines after 48 h, whereas the sub-G1 fraction only increased slightly in the untreated controls or cells treated with gemcitabine or MK-8776 alone.

Consistently, western blot analysis revealed that gemcitabine and MK-8776 treatment for 48 h suppressed the expression of CDK4 and cyclin D1 in bladder cancer cells (Fig. 2b, Fig. S4). However, the combination treatment increased the expression of p21^{CIP1}, a CDK inhibitor, in the 5637 cell line but decreased its expression in the other cell lines investigated. Together, these observations indicate that the combination treatment disturbs the cell cycle distribution and elicits apoptosis.

Gemcitabine and MK-8776 induce apoptosis and necrosis in bladder cancer cells. To characterize the cellular effects of the drug combination in more detail, we investigated the induction of apoptosis. Annexin V/7-amino-actinomycin D (7-AAD) staining revealed that the combination of gemcitabine and MK-8776 suppressed the expression of caspase-3 and caspase-9 in bladder cancer cells (Fig. 3a, Fig. S5), while western blotting demonstrated that the expression of cleaved poly[ADP-ribose]-polymerase (PARP) was enhanced compared to either drug alone (Fig. 3b, Fig. S6). Therefore, these results indicate that the combination treatment elicits apoptosis in bladder cancer cells.

MK-8776 enhances DNA damage induced by gemcitabine. To determine the extent of DNA damage caused by gemcitabine and MK-8776, we analyzed whether the combination treatment induced the expression of γH2A.X, a DSB marker, in bladder cancer cells by western blotting (Fig. 4a, Fig. S7). Exposing bladder cancer cells to the combination of gemcitabine and MK-8776 increased the expression of γH2A.X after 24 and 48 h. We also analyzed the expression of Rad51, which indicates homologous recombination repair activity. The combination treatment decreased Rad51 expression in bladder cancer cells, suggesting that exposure to the combination treatment decreased homologous recombination activity and the accumulation of DNA damage.

To confirm that MK-8776 inhibits CHK1 in bladder cancer cells, we investigated CHK1 signaling (Fig. 4b, Fig. S8). CHK1 phosphorylation at Ser345 was elevated after 24 h of gemcitabine-only treatment and further enhanced by cotreatment with MK-8776, indicating that the coadministration of MK-8776 and gemcitabine induces genotoxic stress. After 48 h, MK-8776 inhibited gemcitabine-induced CHK1 phosphorylation and decreased the expression of the downstream transcriptional target cdc25A, which dephosphorylates cyclin-dependent kinases and regulates the cell cycle. These results indicate that MK-8776 inhibits the activation of checkpoint signaling induced by gemcitabine treatment.
Discussion

This preclinical study evaluated the suitability of the selective CHK1 inhibitor MK-8776 in combination with gemcitabine as a novel therapeutic approach for bladder cancer. Gemcitabine is a ribonucleotide reductase inhibitor that is incorporated into DNA and causes cell cycle arrest in S-phase\textsuperscript{19}. Cell cycle checkpoints are activated by gemcitabine-induced DNA damage, and MK-8776 is known to abrogate cell cycle arrest and aberrant mitosis. Here, we found that the chemosensitizing ability of MK-8776 is associated with the inhibition of gemcitabine-induced CHK activation and the promotion of gemcitabine-induced DNA damage. In particular,
MK-8776 increased CHK1 phosphorylation at Ser345 (ATR-mediated CHK1 phosphorylation) and enhanced DSBs induced by gemcitabine. This is likely associated with its inhibitory effects on homologous recombination, a DSB repair mechanism that uses the undamaged sister chromatid as a repair template during intra-S or G2 phase\textsuperscript{16}. DNA is constantly exposed to a wide range of genotoxic agents. To overcome DNA damage, cells have evolved a complex mechanism known as the DNA damage response, which detects damage and promotes DNA repair\textsuperscript{21}. DNA single-strand breaks are discontinuities in one strand of the DNA duplex that are detected by ATR, which subsequently activates the downstream protein CHK1. Unrepaired single-strand breaks can lead to DNA replication stress and be converted into DSBs during S-phase, resulting in genome instability\textsuperscript{12}. DNA damage responses, particularly ATR-CHK1 signaling, play an important role in therapeutic responses following chemotherapy\textsuperscript{23,24}. Selective CHK1 inhibitors may selectively sensitize p53 defective cancer cells to the cytotoxic effects of gemcitabine since p53 also plays a major role in checkpoint function for many anticancer therapeutics that cause DNA damage\textsuperscript{22,25,26}. Tumor cells with mutated p53 display G1 checkpoint defects and thus rely on the S or G2 checkpoint involving CHKs for DNA repair\textsuperscript{10}. Consequently, CHK inhibition can force p53-defective tumor cells to enter mitosis with unrepaired DNA damage, whereas p53-wild type containing non-tumor cells can overcome this stress by promoting the G1 checkpoint\textsuperscript{10,25}. Notably, p53 function is lost in almost all invasive bladder cancer cells\textsuperscript{12}, thus contributing toward the unusual mode of cell death caused by defective cell cycle checkpoint regulation observed in this study. Conversely, Montano et al. reported that the gemcitabine-sensitizing effects of CHK1 inhibitors were independent of p53 status\textsuperscript{27}. Therefore, future studies should identify novel biomarkers to detect DNA repair defects in bladder cancer cells and thereby predict the response to CHK1 inhibitors.

A phase-I clinical trial showed that MK-8776 is well tolerated with good clinical efficacy both as a monotherapy and in combination\textsuperscript{17}; however, the results of a phase II trial have not yet been announced. Previous studies have shown that MK-8776 can sensitize cells to radiotherapy or histone deacetylase inhibitors, which induce DNA DSBs, via the CHK-related DNA damage response and cell cycle regulation\textsuperscript{8,24}. Moreover, MK-8776 has been shown to restore sensitivity to chemotherapeutic agents in P-glycoprotein-overexpressing cancer cells or re-sensitize cancer cells to the effects of different therapies by inhibiting autophagy\textsuperscript{26,31,32}. However, the exact mechanism by which MK-8776 affects the response to gemcitabine in bladder cancer remains unknown. The in vitro experiments performed in this study revealed that the combination treatment increased the expression of histone H2A.X phosphorylated at Ser 139, yet MK-8776 alone had little effect on γH2A.X. In addition, the co-administration of the four bladder tumor cell lines with MK-8776 and gemcitabine resulted in persistent DNA damage for at least 48 h. To our knowledge, there are currently no clinical trials of MK-8776 in bladder cancer patients, despite these encouraging preclinical results which suggest that its combined use with gemcitabine may be more effective and better tolerated in patients with advanced bladder cancer.

Several previous reports have indicated that p21\textsuperscript{CIP1} regulates transcription in DNA damage response mechanisms, including homologous recombination and cell cycle arrest\textsuperscript{32}. Since p21\textsuperscript{CIP1} is a potent cyclin-dependent kinase (CDK) inhibitor that promotes homologous recombination, increased CDK activity and the inhibition of cell cycle arrest in the absence of p21\textsuperscript{CIP1} increase DNA damage\textsuperscript{33}. In this study, the observed changes in p21\textsuperscript{CIP1} expression were cell line dependent; indeed, 5637 was the only cell line examined in which p21\textsuperscript{CIP1} expression increased following the combination treatment, despite elevated levels of DNA damage. This finding may indicate that MK-8776 suppresses the effect of p21\textsuperscript{CIP1} in the DNA repair process in 5637 cells; however, further studies are required to elucidate the role of p21\textsuperscript{CIP1} in bladder cancer cells in response to CHK1 inhibition.

Despite the important findings, our study had limitations. Firstly, we investigated the effects of pharmacological CHK1 inhibition in four bladder cancer cell lines representing the heterogeneity of bladder cancer; thus, our findings cannot simply be extended to all bladder cancer cells. Further investigations are also required to clarify whether the cytotoxic effect of the combination treatment is related to p53 function or any other characteristics of the cells, including non-tumor cells.

| Gemcitabine (nM) | MK-8776 (μM) |
|------------------|-------------|
|                  | 0.2 | 0.5 | 1.0 |
| 5637             |     |     |     |
| 10               | 0.214 | 0.113 | 0.085 |
| 20               | 0.246 | 0.199 | 0.185 |
| Bl2              |     |     |     |
| 10               | 0.436 | 0.322 | 0.335 |
| 20               | 0.659 | 0.488 | 0.543 |
| T24              |     |     |     |
| 10               | 0.419 | 0.730 | 0.836 |
| 20               | 0.821 | 0.851 | 0.884 |
| UM-UC-3          |     |     |     |
| 10               | 0.188 | 0.118 | 0.088 |
| 20               | 0.228 | 0.193 | 0.152 |

Table 1. Combination indices. Cell viability was used to calculate combination indices (CI) for each investigated cell line using the Chou–Talalay method to determine synergistic effects (CI < 1 indicates synergy).
In conclusion, we found that the combination of gemcitabine and MK-8776 exerted strong antitumor effects on bladder cancer cells. Thus, our study demonstrates the promise of agents that target checkpoint kinases and the DNA replication stress response as a therapeutic strategy to treat bladder cancer. As such, we support the development of this approach to investigate CHK1 inhibitors combined with gemcitabine in clinical studies for patients with advanced bladder cancer.

**Methods**

**Cell culture and reagents.** Four human bladder cancer cell lines (5637, J82, T24, and UM-UC-3) were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in RPMI-1640, MEM, or McCoy’s 5A medium containing 10% FBS and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 °C in a 5% CO2 atmosphere. All cell lines used in the study were p53 mutated. Gemcitabine and MK-8776 were purchased from Selleck Chemicals (Houston, TX, USA).

**MTS assay.** Cancer cells were seeded onto 96-well plates at a density of 3 × 10³ cells/well, allowed to attach for 24 h, and then treated with different concentrations of gemcitabine and/or MK-8776. Cell viability was measured after 48 h using an MTS assay by measuring color intensity with a plate reader at 490 nm (CellTiter 96 Aqueous kit; Promega, Madison, WI, USA) as previously described.

![Figure 2](image-url)
Colony formation assay. Cells were seeded onto 6-well plates at a density of $3 \times 10^3$ cells/well, allowed to attach for 24 h, and then treated with 10 nM gemcitabine and/or 0.5 μM MK-8776 for 24 or 48 h. The cells were then supplied with fresh media and allowed to grow. After 10 days, formed colonies were fixed in 100% methanol and stained with 5% Giemsa (Muto, Tokyo, Japan) for 15 min. Absorbance was measured at 560 nm.

Flow cytometry. For flow cytometry, $2.5 \times 10^4$ cells were cultured in a 6-well plate for 24 h and then treated with different concentrations of gemcitabine and/or MK-8776 for 24 or 48 h. To analyze the cell cycle, detached cells in the supernatant and adherent cells were harvested and stained with propidium iodide. For the annexin

Figure 3. Cell death mechanism induced by the treatments. (a) Flow cytometric analysis of bladder cancer cells treated with indicated conditions after combined staining with Annexin V and 7-AAD. The results are expressed as a percentage of early apoptotic cells (lower right quadrant), late apoptotic cells (upper right quadrant) and necrotic cells (upper left quadrant). (b) PARP cleavage 48 h after the indicated treatments were assessed by western blotting. Actin was used as a loading control. A quantification of the signals is illustrated in Fig. S5.

Figure 4. Western blot analysis of checkpoint factors. (a) γH2A.X and Rad51 protein expression following the indicated treatment. Actin was used as a loading control. A quantification of the signals is illustrated in Fig. S6. (b) Expression of cell checkpoint-related proteins and their phosphorylation in whole-cell lysates. Actin was used as a loading control. A quantification of the signals is illustrated in Fig. S7.
V assay, harvested cells were stained with annexin V-FITC to detect apoptosis and with 7-AAD to detect necrosis following the manufacturer’s instructions (Beckman Coulter, Marseille, France). Flow cytometry data were acquired and analyzed using CellQuest Pro software (BD Biosciences, San Jose, CA, USA).

**In vivo experiments.** All procedures carried out in this study were approved by the Institutional Animal Care and Use Committee of the National Defense Medical College (approval number 14068). The study was carried out in compliance with the ARRIVE guidelines. Subcutaneous tumor nodules were generated by injecting UM-UC-3 cells (1 × 10⁶ cells) into the flanks of five-week-old male BALB/c Slc-nu/nu mice obtained from CLEA (Tokyo, Japan) 5 days before treatment initiation. Mice were then intraperitoneally administered gemcitabine (20 mg/kg) and/or MK-8776 (4 mg/kg) or the vehicle control (DMSO) once daily from day 1 (n = 5 per group) for two weeks. Mice were carefully monitored, and two perpendicular diameters of the subcutaneous tumor were measured with calipers every two or three days. Tumor size was determined by calculating tumor length and width (tumor volume = 0.5 × length × width²), and differences between the four treatment groups were analyzed using the Mann–Whitney U test. Body weight was measured every week. Mice were killed on day 15 according to ethical policies for animal research. All applicable international, national, and institutional guidelines for the care and use of animals were followed.

**Western blot analysis.** Total protein lysates were obtained using RIPA-buffer (0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate, 1% Nonidet P-40, 150 mM NaCl, 1% Triton X-100, 50 mM Tris (pH 7.6), 1 mM EDTA, and 10 µL/mL protease inhibitor cocktail; Sigma Aldrich, St. Louis, MO, USA). Equal amounts of protein from each sample were loaded onto SDS-PAGE gels and wet-blotted onto nitrocellulose membranes which were then blocked with 5% BSA or skimmed milk in TBS with 0.2% Tween-20 (TBS-T) and incubated with the following primary antibodies at 4 °C overnight: anti-CDK 4, anti-cyclin D1, p21CIP1 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA, USA), active caspase 3 (1:500, Epitomics, Burlingame, CA, USA), PARP, cleaved PARP, phosphorylated CHK1 (Ser345), CHK1, pH2A.X, and Rad51 (1:1000, Cell Signaling Technology, Danvers, MA, USA). Anti-actin antibodies (1:3000 dilution; Millipore, Billerica, MA, USA) were used as a loading control. Membranes were washed three times in TBS-T and incubated with horseradish peroxidase-labeled secondary antibodies (1:6000 dilution; Millipore, Billerica, MA, USA). Anti-actin antibodies were visualized using an enhanced chemiluminescence detection system (ECL Plus Western Blotting Detection Antibodies, 1:6000 dilution; Bio-Rad, Hercules, CA, USA) for 1 h before being washed again. Labeled proteins following primary antibodies at 4 °C overnight: anti-CDK 4, anti-cyclin D1, p21CIP1 (1:250, Santa Cruz Biotechnology, Santa Cruz, CA, USA), active caspase 3 (1:500, Epitomics, Burlingame, CA, USA), PARP, cleaved PARP, phosphorylated CHK1 (Ser345), CHK1, pH2A.X, and Rad51 (1:1000, Cell Signaling Technology, Danvers, MA, USA). Anti-actin antibodies (1:3000 dilution; Millipore, Billerica, MA, USA) were used as a loading control. Membranes were washed three times in TBS-T and incubated with horseradish peroxidase-labeled secondary antibodies (1:6000 dilution; Millipore, Billerica, MA, USA) for 1 h before being washed again. Labeled proteins were detected using an enhanced chemiluminescence detection system (ECL Plus Western Blotting Detection System; GE Healthcare, Wauwatosa, WI, USA). Protein amounts were calculated relative to the actin reference protein and refractory acute myeloid leukemia. Leuk. Res. 61, 108–116 (2017).

**Statistical analysis.** The Chou–Talalay method was used to calculate combination indices (CalcuSyn software, Biosoft, Cambridge, UK). The Mann–Whitney U test was used to analyze differences between groups in StatView software (SAS Institute, Cary, NC, USA). Differences were considered significant for p values of <0.05.

**Data availability** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 6 October 2020; Accepted: 26 April 2021

Published online: 13 May 2021

**References**

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. *C. A. Cancer J. Clin.* 69, 7–34 (2019).

2. Milowsky, M. I. *et al.* Guideline on muscle-invasive and metastatic bladder cancer (European association of urology guideline): American society of clinical oncology clinical practice guideline endorsement. *J. Clin. Oncol.* 34, 1945–1952 (2016).

3. von der Maase, H. *et al.* Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. *J. Clin. Oncol.* 23, 4602–4608 (2005).

4. Dash, A. *et al.* Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. *Cancer* 107, 506–513 (2006).

5. Rosenberg, J. E. *et al.* Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 17, 1909–1920 (2016).

6. Hoeijmakers, J. H. *et al.* Genome maintenance mechanisms for preventing cancer. *Nature* 411, 366–374 (2001).

7. Sancar, A. *et al.* Mammalian DNA repair and the DNA damage checkpoints. *Annu. Rev. Biochem.* 73, 39–85 (2004).

8. Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. *Science* 300, 1542–1548 (2003).

9. Bartek, J. & Lukas, J. CHK1 and Chk2 kinases in checkpoint control and cancer. *Cancer Cell* 10, 421–429 (2003).

10. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. *Mol. Cancer Ther.* 3, 513–519 (2004).

11. Zhou, B. B. & Bartek, J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. *Nat. Rev. Cancer* 4, 216–225 (2004).

12. Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. *Nat. Rev. Cancer* 15, 25–41 (2015).

13. Zheng, L. *et al.* Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis. *OncoLett.* 15, 568–574 (2018).

14. Huang, P. *et al.* Action of 2',2'-difluorodeoxycytidine on DNA synthesis. *Cancer Res.* 51, 610–6117 (1991).

15. Karnitz, L. M. *et al.* Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. *Mol. Pharmacol.* 68, 1636–1644 (2005).

16. Webster, J. A. *et al.* Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. *Leuk. Res.* 61, 108–116 (2017).
17. Daud, A. I. et al. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. *J. Clin. Oncol.* 33, 1060–1066 (2015).
18. Bonner, W. M. et al. GammaH2AX and cancer. *Nat. Rev. Cancer* 8, 957–967 (2008).
19. Montano, R. et al. Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: Implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor. *Oncotarget* 8, 67754–67768 (2017).
20. Man, Z., Bozzella, M., Seluanov, A. & Gorbunova, V. Comparison of nonhomologous end joining and homologous recombination in human cells. *DNA Repair (Amst.)* 7, 1765–1771 (2008).
21. Ciccia, A. & Elledge, S. J. The DNA damage response: Making it safe to play with knives. *Mol. Cell* 40, 179–204 (2010).
22. Caldecott, K. W. Single-strand break repair and genetic disease. *Nat. Rev. Genet.* 9, 619–631 (2008).
23. Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. *Nat. Rev. Cancer* 12, 587–598 (2012).
24. Li, C. C. et al. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer. *Oncotarget* 7, 1947–1959 (2016).
25. Wang, W. T., Catto, J. W. & Meuth, M. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors. *Oncogene* 34, 2887–2896 (2015).
26. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* 434, 864–870 (2005).
27. Montano, R. et al. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: Cell cycle perturbation and impact of administration schedule in vitro and in vivo. *BMC Cancer* 13, 604 (2013).
28. Dai, Y. et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. *Mol. Cancer Ther.* 12, 878–889 (2013).
29. Bridges, K. A. et al. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. *Oncotarget* 7, 71660–71672 (2016).
30. Cui, Q. et al. Chk1 inhibitor MK-8776 restores the sensitivity of chemotherapeutics in P-glycoprotein overexpressing cancer cells. *Int. J. Mol. Sci.* 20, 4095 (2019).
31. Zhou, Z. R. et al. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. *Acta. Pharmacol. Sin.* 38, 513–523 (2017).
32. Dutto, L., Tillhon, M., Cazzalini, O., Stivala, L. A. & Prosperi, E. Biology of the cell cycle inhibitor p21(CDKN1A): Molecular mechanisms and relevance in chemical toxicity. *Arch. Toxicol.* 89, 155–178 (2015).
33. Mauro, M. et al. p21 promotes error-free replication-coupled DNA double-strand break repair. *Nucleic Acids Res.* 40, 8348–8360 (2012).
34. Okubo, K., Isono, M., Miyai, K., Asano, T. & Sato, A. Fluvasstatin potentiates anticancer activity of vorinostat in renal cancer cells. *Cancer Sci.* 111, 112–126 (2020).
35. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. *Br. J. Cancer* 102, 1555–1577 (2010).
36. Guzman, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: An ImageJ plugin to automatically quantify colony formation in clongenic assays. *PLoS ONE* 9, e92444 (2014).

**Acknowledgements**

We would like to thank Editage (www.editage.com) for English language editing.

**Author contributions**

M.I., K.O., and A.S. conceived and designed the study. M.I. performed most of the experiments. T.A. carried out additional experiments. A.S. supervised the project. M.I. prepared the initial manuscript. K.O., T.A., and A.S. contributed toward the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-89684-5.

**Correspondence** and requests for materials should be addressed to M.I.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021